Publicaciones (135) Publicaciones de Enrique Bernal Morell

2024

  1. Clinical and Epidemiological Characteristics of the 2022 Mpox Outbreak in Spain (CEME-22 Study)

    Open Forum Infectious Diseases, Vol. 11, Núm. 3

  2. Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 6, pp. 553-561

  3. HLA-C*07 is associated with symptomatic HIV-1-associated neurocognitive disorders (HAND) and immune dysregulation

    Infectious Diseases

  4. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study

    Critical care medicine, Vol. 52, Núm. 6, pp. 930-941

  5. Low-level HIV viraemia during antiretroviral therapy: Longitudinal patterns and predictors of viral suppression

    HIV Medicine, Vol. 25, Núm. 1, pp. 107-116

  6. Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study

    Open Forum Infectious Diseases, Vol. 11, Núm. 1

2023

  1. A Randomized Trial of Dolutegravir Plus Darunavir/ Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes

    Open Forum Infectious Diseases, Vol. 10, Núm. 11

  2. Age-dependent association of clonal hematopoiesis with COVID-19 mortality in patients over 60 years

    GeroScience, Vol. 45, Núm. 1, pp. 543-553

  3. Correction: Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection (Trials, (2021), 22, 1, (851), 10.1186/s13063-021-05777-6)

    Trials

  4. Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events

    EBioMedicine, Vol. 95, pp. 104773

  5. Failure of Non-Invasive Respiratory Support in Patients with SARS-CoV-2

    Journal of Clinical Medicine, Vol. 12, Núm. 20

  6. IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors

    Frontiers in Immunology, Vol. 14

  7. Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 8, pp. 435-443

  8. Remdesivir plus dexamethasone is associated to improvement in the clinical outcome of COVID-19 hospitalized patients regardless of their vaccination status

    Medicina Clinica, Vol. 161, Núm. 4, pp. 139-146

  9. Role of vaccination and anti-SARS-CoV-2 antibodies in the clinical outcome of hospitalized COVID-19 patients

    Medicina Clinica, Vol. 160, Núm. 11, pp. 476-483

  10. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701

  11. Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses

    BMC Infectious Diseases, Vol. 23, Núm. 1

  12. Whole Sequencing and Detailed Analysis of SARS-CoV-2 Genomes in Southeast Spain: Identification of Recurrent Mutations in the 20E (EU1) Variant with Some Clinical Implications

    Diseases, Vol. 11, Núm. 2

2022

  1. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

    JHEP Reports, Vol. 4, Núm. 5

  2. Circulating suPAR associates with severity and in-hospital progression of COVID-19

    European Journal of Clinical Investigation, Vol. 52, Núm. 7